The clinical efficacy of TYK2 inhibitors in inflammatory and autoimmune diseases has been demonstrated (Gonciarz et al., 2021), as evidenced by genomic, transcriptomic, and proteomic analyses detecting TYK2 mutations and expression changes in various tumors (Hammarén et al., 2019). This evidence concerns the gene TYK2 and autoimmune disease.